Abbott Laboratories v. Baxter Int'l Inc , 218 F. App'x 523 ( 2007 )


Menu:
  •                             NONPRECEDENTIAL DISPOSITION
    To be cited only in accordance with Fed. R. App. P. 32.1
    United
    To be citedStates       Court
    only in accordance      of R.Appeals
    with Fed.  App. P.
    32.1Not to be cited per Circuit Rule 53
    For the Seventh Circuit
    Chicago, Illinois 60604
    Submitted February 13, 2007∗
    Decided March 5, 2007
    Before
    Hon. FRANK H. EASTERBROOK, Chief Judge
    Hon. RICHARD D. CUDAHY, Circuit Judge
    Hon. TERENCE T. EVANS, Circuit Judge
    No. 06-3799
    Appeal from the United
    ABBOTT LABORATORIES,                                         States District Court for the
    Plaintiff-Appellant,                                    Northern District of Illinois,
    Eastern Division.
    v.
    No. 01 C 4809
    BAXTER INTERNATIONAL, INCORPORATED,                          Ronald A. Guzmán, Judge.
    Defendant-Appellee.
    Order
    An arbitral tribunal’s award required Baxter International to refrain from
    competing in the market for sevoflurane until December 2005. This restraint was
    ancillary to licensing agreements concerning sevoflurane made by a patented
    process, and we held that the award was lawful and had been properly confirmed by
    the district court. See Baxter International, Inc. v. Abbott Laboratories, 
    315 F.3d 829
     (7th Cir. 2003).
    As the time when the patents were to expire and Baxter again could sell
    sevoflurane approached, it began to make marketing plans and to contact potential
    customers. It negotiated several deals that would take effect when it could resume
    deliveries. Abbott Laboratories does not contend that Baxter delivered any
    ∗ After examining the briefs and the record, we have concluded that oral argument is
    unnecessary. See Fed. R. App. P. 34(a); Cir. R. 34(f).
    No. 06-3799                                                              Page 2
    sevoflurane in advance of the date specified in the award but maintains that the
    initial steps of planning to make sales, and of negotiating with potential customers,
    violate the award. It asked the district court to hold Baxter in contempt of court and
    appeals from the order rejecting this request.
    The award requires Baxter “not to market, whether directly or indirectly, the
    inhalation anesthetic known as Sevoflurane in the Territory defined in the” licenses
    until December 11, 2005. Abbott observes that, in both a colloquial and a dictionary
    sense, activities that promote the sale of a product “market” that product even
    though they do not result in immediate deliveries. The district court granted that
    premise but observed that “to market” likewise can mean “to sell”. A litigant should
    not be held in contempt, the district court wrote, unless it has violated an
    unambiguous command. See Tranzact Technologies, Inc. v. 1Source Worldsite, 
    406 F.3d 851
    , 855 (7th Cir. 2005). This command was ambiguous, the district court
    concluded--adding that in its view Baxter’s reading (which equates “market” with
    “sell”) is the preferable one.
    We agree with the district court’s conclusion that the phrase is ambiguous. It
    could mean “do not engage in sales promotions until December 11, 2005” or “do not
    deliver to customers until December 11, 2005.” One need look no further than the
    district court’s opinion to see the problem. It would be more than a little strange to
    hold that Baxter had violated an unambiguous command, when the district court
    itself agreed with Baxter’s reading--and with a good deal of sense.
    The award is designed to keep Baxter out of the sevoflurane business during
    the term of the patent and licenses, not to protect Abbott beyond that term. If
    Baxter could not begin to approach potential customers until December 11, 2005,
    then as a practical matter Abbott would have the market to itself for all of
    December 2005 and perhaps much of 2006, for many customers commit to long-term
    purchase contracts. Customers shopping for sevoflurane during 2005 for delivery
    during 2006 were entitled to know that during 2006 Baxter could supply their
    needs.
    Whether or not this is an inevitable understanding of the award, it is not
    such an idiosyncratic one that the district court abused its discretion (the applicable
    standard of review, see Stotler & Co. v. Able, 
    870 F.2d 1158
    , 1163 (7th Cir. 1989)) by
    refusing to hold Baxter in contempt of court.
    AFFIRMED
    

Document Info

Docket Number: 06-3799

Citation Numbers: 218 F. App'x 523

Judges: Per Curiam

Filed Date: 3/5/2007

Precedential Status: Non-Precedential

Modified Date: 1/12/2023